National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Teclistamab (Tecvayli®). HTA ID: 22064

Teclistamab (Tecvayli®) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 20/09/2022
Rapid review completed 03/11/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teclistamab compared with the current standard of care.